If you ask most people what mRNA is, they will likely scratch their heads and, if you’re lucky, draw a vague connection to Covid-19 shots. The acronym for ‘messenger ribonucleic acid’ entered the public consciousness during the pandemic as the foundation of preventive treatment against the virus.
How does it work? In simple terms, mRNA is a set of instructions your cells use to make specific proteins that help your body function and stay healthy. The Covid-19 vaccine is a well-known example of this technology in use, which essentially trains the body to combat the disease by stimulating an immune response.
Helping populations around the world protect themselves against one of the most virulent diseases to emerge in living memory is one way that physicians have used mRNA. Innorna, a biotechnology company specializing in mRNA engineering and lipid nanoparticle (LNP) delivery platforms, is advancing a potentially world’s first bivalent mRNA vaccine candidate against respiratory syncytial virus (RSV)—IN006, which targets both RSV-A and RSV-B—into clinical trials.
Innorna sees mRNA as adding flexibility to a vaccine in case of viral mutation. The bivalent nature of the vaccine means it can cover both RSV subtypes that currently exist. This design aims to provide broad-spectrum and durable protection.
A milestone in RSV prevention: IN006 completes phase 2 clinical study enrollment
In a significant step forward, Innorna has completed enrolment and vaccination in its Phase 2 clinical trial for IN006. This milestone marks a key step in the development of this innovative vaccine candidate, which is also recognized as China’s first domestically developed RSV vaccine to enter clinical trials.
The Phase 2 study is a randomized, double-blind, placebo-controlled trial conducted in China among healthy adults aged 60 and above. It is a critical step for dose optimization, broader population validation, and evaluating a booster shot for annual revaccination. This progress sets a solid foundation for subsequent Phase 3 efficacy studies.
“This Phase 2 clinical trial marks a critical step in validating IN006’s scientific hypothesis—delivering broad-spectrum, durable protection against RSV,” said Dr. Linxian Li, Founder and CEO of Innorna. “We remain committed to advancing the clinical development of this vaccine candidate efficiently. Our goal is to deliver safer, more effective RNA medicines to meet global public health needs.”
Dr. Linxian Li, Founder and CEO of Innorna
Addressing a critical public health gap
RSV is a highly contagious virus that poses elevated risks to older adults, young children, immunocompromised individuals, and those with chronic conditions—potentially leading to pneumonia, respiratory failure, or death.
With no approved antiviral treatment and no authorized RSV vaccine in China, the need for effective prevention remains critical. IN006 represents a major step in public health innovation to fill this void.
Built on a proprietary technology platform
IN006 is built on Innorna’s proprietary pre-fusion F protein design, mRNA, and LNP platforms. Preclinical studies showed a favorable safety profile and strong humoral and cellular immune responses. In the preclinical cotton rat challenge study, IN006 provided effective protection against both RSV-A and RSV-B.
Innorna’s expertise in LNP enables it to serve as a platform licensor for vaccine and drug delivery. The company’s proprietary, rationally designed lipid library comprising over 6,000 chemically diverse ionizable lipids enables breakthroughs in mRNA vaccines and therapeutics.
Leaping into unchartered territories to make medical miracles
Hong Kong Science and Technology Parks (HKSTP) is a launchpad for startups like Innorna to scale globally.
Since forming Innorna six years ago, Dr. Li says the infrastructural support that Hong Kong Science and Technology Parks Corporation (HKSTP) provides has also been vital in taking the company to where it is today.
“We have received a lot of support from HKSTP, which has included both funding and other essential resources,” he explains. “They also help us connect with potential collaborators, which is very important for us because in the end, whatever groundbreaking treatments we may develop, we need to be able to commercialise them.”
In a field where preventive options are still limited, Innorna is applying big science to a pervasive viral challenge. The company’s work on IN006 aims to bring a powerful new tool to the global fight against RSV. This candidate has the potential to benefit a broad population and reshape the landscape of respiratory disease prevention.
—
Want updates like this delivered directly? Join our WhatsApp channel and stay in the loop.
This article is sponsored by HKSTP
We can share your story at e27 too! Engage the Southeast Asian tech ecosystem by bringing your story to the world. You can reach out to us here to get started.
Featured Image Credit: HKSTP, Innorna, Canva Images
The post Rewriting the future of RSV prevention: Innorna’s bivalent mRNA vaccine accelerates toward patients appeared first on e27.